학술논문

Interim safety analysis of nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecular-selected patients (pts) with metastastic castration-resistant prostate cancer (mCRPC)
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2022, 33 7, pS1177-pS1178, 2p. Supplement: 7
Subject
Language
English
ISSN
15698041